Recent research indicates that CDC42 plays a role in the pathogenesis of kidney disorders such as congenital nephrotic syndrome or glomerulosclerosis because it is necessary for the correct function of renal podocyte and tubule.

Recent findings suggest gut microbiota dysbiosis may be behind the inflammation in diabetic nephropathy (DN), the leading cause of end-stage renal disease (ESRD).

Acute kidney injury (AKI) is a common disease with high morbidity that still lacks effective drug treatments. The death of tubular epithelial cells is the principal basis for AKI. This cell death in AKI does not occur by necrosis but by other cell death mechanisms such as pyroptosis, among others. Recent findings have implicated chromodomain Y-like (CDYL) in autosomal dominant polycystic kidney disease, but its role in AKI has not been established.

Meta Pharmaceuticals Inc. announced that the FDA has granted rare pediatric disease designation to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH), an autosomal recessive metabolic disorder in which oxalate is overproduced and deposited in the body.

An antibody that binds to the latent form of transforming growth factor-β1 (TGF-β1) prevented its release into the extracellular matrix and reduced the progression of fibrosis in the kidney. TGF-β is synthesized and secreted into the extracellular matrix in a latent inactive form associated with the latency peptide.

Dent disease (DD) is an X-linked recessive disorder characterized by low molecular weight proteinuria (LMWP), kidney stones and progressive kidney failure.

OTU deubiquitinase 5 (OTUD5) is a deubiquitinating enzyme that has been shown to play a key role in mediating innate immunity and inflammation development, and which is also involved in various cancers.

Eleva is preparing a first clinical study in this indication, with dosing slated to begin in in the first half of next year.